Bibliographic Details
| Title: |
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. |
| Authors: |
Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR, McMorrow ML, Dawood FS |
| Corporate Authors: |
New Vaccine Surveillance Network Product Effectiveness Collaborators |
| Source: |
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Mar 07; Vol. 73 (9), pp. 209-214. Date of Electronic Publication: 2024 Mar 07. |
| Publication Type: |
Journal Article |
| Journal Info: |
Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
